On-line Treatment for Conduct Problems

February 19, 2026 updated by: Yale University
The research evaluates the use of online versions of delivering an effective psychological treatment for children clinically referred for serious oppositional, aggressive, and antisocial behavior. The goal is to develop models of delivery that reach families in need that are not being served by in-person treatment. The project has immediate implications for the treatment of children but more generally addresses several issues critical to treatments that are based on Internet, telepsychiatry, and related technologies.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
86

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Connecticut
      • New Haven, Connecticut, United States, 06511
        • Yale Parenting Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

6 years to 12 years (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of Conduct Disorder of Oppositional Defiant Disorder (for the child)
  • Residence in the state of CT
  • Access to a computer and high-speed Internet access
  • English fluency (at least one parent)
  • No history of significant developmental delay (for the child)
  • Parental consent

Exclusion Criteria:

  • Participation in another form of psychotherapy or counseling that is directed toward the reduction of social, emotional, or behavioral problems
  • Evidence of recent suicidality (for the child)
  • Current or lifetime diagnosis of a Pervasive Developmental Disorder
  • Primary diagnoses of a mood or anxiety disorder
  • Acute family crisis
  • Parent or guardian who can participate in treatment shows current psychosis or an uncontrolled medical condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Online treatment, High therapist contact
Participants receive online Parent Management Training (interactive).
Behavioral: Online Parent Management Training (Interactive)
Experimental: Online treatment, Low therapist contact
Participants receive online Parent Management Training (recorded).
Behavioral: Online Parent Management Training (Recorded)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Child Behavior Checklist
Time Frame: Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Internalizing and externalizing behavior problems in children
Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Child Global Assessment Scale
Time Frame: Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Therapist-rated measure of overall child impairment and functioning
Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Interview for Antisocial Behavior
Time Frame: Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Presence of a broad range of overt and covert antisocial behaviors in children
Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Research Diagnostic Interview
Time Frame: Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Clinical symptoms and diagnoses based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria
Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Parenting Stress Index
Time Frame: Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Sources of stress for the parent
Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Beck Depression Inventory
Time Frame: Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Parental symptoms of depression
Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Management of Child Behavior Scale
Time Frame: Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Parenting practices
Change from pretreatment (Week 0; immediately before the start of treatment) to posttreatment (immediately after treatment is completed; Week 8)
Parent-Therapist Relationship Scale (Therapist version)
Time Frame: Midtreatment (Week 4 of treatment)
Characteristics of the therapeutic relationship according to therapist report
Midtreatment (Week 4 of treatment)
Parent-Therapist Relationship Scale (Therapist version)
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Characteristics of the therapeutic relationship according to therapist report
Posttreatment (immediately after treatment is completed; Week 8)
Parent-Therapist Relationship Scale (Parent version)
Time Frame: Midtreatment (Week 4 of treatment)
Characteristics of the therapeutic relationship according to parent report
Midtreatment (Week 4 of treatment)
Parent-Therapist Relationship Scale (Parent version)
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Characteristics of the therapeutic relationship according to parent report
Posttreatment (immediately after treatment is completed; Week 8)
Barriers to Participation in Treatment (Therapist version)
Time Frame: Midtreatment (Week 4 of treatment)
Stressors and obstacles that interfere with treatment
Midtreatment (Week 4 of treatment)
Barriers to Participation in Treatment (Therapist version)
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Stressors and obstacles that interfere with treatment
Posttreatment (immediately after treatment is completed; Week 8)
Barriers to Participation in Treatment (Parent version)
Time Frame: Midtreatment (Week 4 of treatment)
Stressors and obstacles that interfere with treatment
Midtreatment (Week 4 of treatment)
Barriers to Participation in Treatment (Parent version)
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Stressors and obstacles that interfere with treatment
Posttreatment (immediately after treatment is completed; Week 8)
Weekly Participation in Treatment
Time Frame: Weekly (during treatment)
Attendance and participation in treatment sessions
Weekly (during treatment)
Treatment Adherence Inventory (Therapist version)
Time Frame: Midtreatment (Week 4 of treatment)
Parental compliance with specific treatment techniques
Midtreatment (Week 4 of treatment)
Treatment Adherence Inventory (Therapist version)
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Parental compliance with specific treatment techniques
Posttreatment (immediately after treatment is completed; Week 8)
Treatment Adherence Inventory (Parent version)
Time Frame: Midtreatment (Week 4 of treatment)
Parental compliance with specific treatment techniques
Midtreatment (Week 4 of treatment)
Treatment Adherence Inventory (Parent version)
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Parental compliance with specific treatment techniques
Posttreatment (immediately after treatment is completed; Week 8)
Therapist Evaluation Inventory
Time Frame: Midtreatment (Week 4 of treatment)
Acceptability of treatment based on therapist report
Midtreatment (Week 4 of treatment)
Therapist Evaluation Inventory
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Acceptability of treatment based on therapist report
Posttreatment (immediately after treatment is completed; Week 8)
Parent Evaluation Inventory
Time Frame: Midtreatment (Week 4 of treatment)
Acceptability of treatment based on parent report
Midtreatment (Week 4 of treatment)
Parent Evaluation Inventory
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Acceptability of treatment based on parent report
Posttreatment (immediately after treatment is completed; Week 8)
Acceptability of Treatment Modality
Time Frame: Midtreatment (Week 4 of treatment)
Parent-report measure rating the acceptability of online treatment and barriers that may affect participants receiving online treatment specifically
Midtreatment (Week 4 of treatment)
Acceptability of Treatment Modality
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Parent-report measure rating the acceptability of online treatment and barriers that may affect participants receiving online treatment specifically
Posttreatment (immediately after treatment is completed; Week 8)

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Perspectives on Treatment Interview
Time Frame: Posttreatment (immediately after treatment is completed; Week 8)
Open-ended interview questions about parents' experiences in treatment and their impressions of different aspects of online treatment delivery
Posttreatment (immediately after treatment is completed; Week 8)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Yale University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institute of Mental Health (NIMH)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Alan E. Kazdin, Ph.D., Yale University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2012

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2014

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2014

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 22, 2013

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 27, 2013

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 2, 2013

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 23, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 19, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 1108008914
  • 1R34MH093326-01A1 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings